Jacob M Rowe

List of Publications by Year in Descending Order

275 papers	14,776 citations	51 h-index	120 g-index
304 ext. papers	16,812 ext. citations	4.8 avg, IF	6.13 L-index

#	Paper	IF	Citations
275	The predictive value of a positive phase II ASH abstract for peer-reviewed publication and progression to phase III.. *Blood*, **2022**,	2.2	1
274	Toward further excellence in .. *Haematologica*, **2022**, 107, 2	6.6	
273	The "7+3" regimen in acute myeloid leukemia.. *Haematologica*, **2022**, 107, 3	6.6	2
272	Anti-CD20 monoclonal antibodies inhibit seropositive response to Covid-19 vaccination in Non-Hodgkin lymphoma patients within six months after treatment.. *Experimental Hematology*, **2021**,	3.1	3
271	Allogeneic Transplantation in Fit Older Adults Is Feasible and Encouragingly Efficacious. Post Remission Data from the Prospective ECOG-ACRIN (E2906) Clinical Study. *Blood*, **2021**, 138, 413-413	2.2	0
270	Patients with AML Who Achieve Long Term Complete Remission Do Not Have a Normal Life Expectancy When Compared to the General Population. Analysis of 3,012 Patients Enrolled on 9 Consecutive ECOG-ACRIN Trials. *Blood*, **2021**, 138, 690-690	2.2	
269	Most ASH Abstracts Reporting Phase II Studies Lead to Peer-Reviewed Publications, but Less Than 50% of "Positive" Abstracts Lead to Phase III Investigations: An Analysis of 371 Abstracts 2013 - 2015. *Blood*, **2021**, 138, 4040-4040	2.2	
268	Emerging Monoclonal Antibody Therapy for the Treatment of Acute Lymphoblastic Leukemia. *Biologics: Targets and Therapy*, **2021**, 15, 419-431	4.4	0
267	Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial. *Leukemia Research*, **2021**, 111, 106736	2.7	0
266	Changing trends in the therapy of acute myeloid leukemia. *Best Practice and Research in Clinical Haematology*, **2021**, 34, 101333	4.2	1
265	Perspectives on current survival and new developments in AML. *Best Practice and Research in Clinical Haematology*, **2021**, 34, 101248	4.2	3
264	Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL. *Blood*, **2021**, 138, 948-958	2.2	7
263	Efficacy and safety of aspacytarabine (BST-236) as a single-agent, first-line therapy for patients with acute myeloid leukemia unfit for standard chemotherapy.. *Journal of Clinical Oncology*, **2021**, 39, 7007-7007	2.2	1
262	Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence. *Blood and Lymphatic Cancer: Targets and Therapy*, **2021**, 11, 41-54	2.6	3
261	Prognostic effect of gender on outcome of treatment for adults with acute myeloid leukaemia. *British Journal of Haematology*, **2021**, 194, 309-318	4.5	3
260	Enhancer Hijacking Drives Oncogenic Expression in Lineage-Ambiguous Stem Cell Leukemia. *Cancer Discovery*, **2021**, 11, 2846-2867	24.4	12
259	BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study. *Cancer*, **2021**, 127, 1246-1259	6.4	6

258	Inhibition of FLT3: A Prototype for Molecular Targeted Therapy in Acute Myeloid Leukemia. *Engineering*, **2021**, 7, 1354-1354	9.7	
257	Consolidation in AML: Abundant opinion and much unknown. *Blood Reviews*, **2021**, 51, 100873	11.1	0
256	CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trials. *Blood Advances*, **2021**, 5, 4560-4568	7.8	3
255	Venetoclax is safe and efficacious in relapsed/refractory AML. *Leukemia and Lymphoma*, **2020**, 61, 2221-2225	2.9	15
254	At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial. *British Journal of Haematology*, **2020**, 191, 37-43	4.5	5
253	Survival following allogeneic transplant in patients with myelofibrosis. *Blood Advances*, **2020**, 4, 1965-1973	7.8	23
252	A novel PrECOG (PrE0901) dose-escalation trial using eltrombopag: enhanced platelet recovery during consolidation therapy in acute myeloid leukemia. *Leukemia and Lymphoma*, **2020**, 61, 2191-2199	1.9	2
251	How we treat older patients with acute myeloid leukaemia. *British Journal of Haematology*, **2020**, 191, 682-691	4.5	2
250	Durable Remissions and Increased Overall Survival in AML Patients Deemed Unfit for Standard Intensive Chemotherapy Achieved with High-Dose BST-236 (Aspacytarabine) Induction and Consolidation. *Blood*, **2020**, 136, 9-10	2.2	
249	Safety and Demonstrated Efficacy of Placenta-Derived Cell Therapy PLX-R18 in Subjects with Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation: A Phase I International Multi-Center Study. *Blood*, **2020**, 136, 24-25	2.2	0
248	Forward into the second century of Haematologica. *Haematologica*, **2020**, 105, 2498	6.6	
247	Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. *Biology of Blood and Marrow Transplantation*, **2020**, 26, 472-479	4.7	7
246	Bone marrow blast elimination by the fifth day of 7 + 3 induction is the strongest predictor of potential cure in patients with acute myeloid leukemia younger than 61 years of age: A long-term follow-up of a multi-center prospective study. *American Journal of Hematology*, **2020**, 95, E3-E5	7.1	
245	Pharmacological prophylaxis of infection in pediatric acute myeloid leukemia patients. *Expert Opinion on Pharmacotherapy*, **2020**, 21, 193-205	4	1
244	Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia. *Nature Cancer*, **2020**, 1, 1113-1127	15.4	7
243	Newly diagnosed myeloma patients with low-burden disease may benefit from tandem autologous stem cell transplantation: results of long-term follow-up. *Bone Marrow Transplantation*, **2020**, 55, 1200-1202	4.4	
242	Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 2113-2123	4.7	38
241	Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study. *Lancet Haematology,the*, **2019**, 6, e122-e131	14.6	14

240	The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900). *Leukemia Research*, **2019**, 78, 29-33	2.7	1
239	Efficacy outcomes in the treatment of older or medically unfit patients with acute myeloid leukaemia: A systematic review and meta-analysis. *Leukemia Research*, **2019**, 82, 36-42	2.7	15
238	Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation. *Leukemia and Lymphoma*, **2019**, 60, 2449-2456	1.9	8
237	Advances in BCR/ABL positive ALL. *Advances in Cell and Gene Therapy*, **2019**, 2, e60	1.2	
236	Venetoclax Is Safe and Efficacious in Relapsed/ Refractory AML. *Blood*, **2019**, 134, 5091-5091	2.2	1
235	A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia. *Blood*, **2019**, 134, 2662-2662	2.2	8
234	Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML). *Blood*, **2019**, 134, 1309-1309	2.2	8
233	Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study. *Blood*, **2019**, 134, 115-115	2.2	12
232	The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. *Blood Advances*, **2019**, 3, 670-680	7.8	35
231	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. *Blood Advances*, **2019**, 3, 1826-1836	7.8	50
230	BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study. *Blood Advances*, **2019**, 3, 3740-3749	7.8	5
229	Will new agents impact survival in AML?. *Best Practice and Research in Clinical Haematology*, **2019**, 32, 101094	4.2	11
228	Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900. *Haematologica*, **2019**, 104, e147-e150	6.6	4
227	PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. *Nature Genetics*, **2019**, 51, 296-307	36.3	189
226	A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease. *American Journal of Hematology*, **2019**, 94, 111-117	7.1	19
225	Primary plasma cell leukemia in the era of novel agents for myeloma - a multicenter retrospective analysis of outcome. *Leukemia Research*, **2018**, 68, 9-14	2.7	10
224	Revisiting autologous transplantation in acute myeloid leukemia. *Current Opinion in Hematology*, **2018**, 25, 95-102	3.3	6
223	Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 945-955	4.7	5

222	Daratumumab for relapsed/refractory Philadelphia-positive acute lymphoblastic leukemia. *Haematologica*, **2018**, 103, e489-e490	6.6	19
221	Advances in the genetics of acute lymphoblastic leukemia in adults and the potential clinical implications. *Expert Review of Hematology*, **2018**, 11, 781-791	2.8	5
220	Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience. *American Journal of Hematology*, **2018**, 93, 1074-1081	7.1	45
219	Daratumumab in Combination with Vincristine or Nelarabine As Effective Salvage Therapy for Patients with Acute Lymphoblastic Leukemia at High Risk of Relapse. *Blood*, **2018**, 132, 5206-5206	2.2	5
218	Minimal Residual Disease (MRD) at Time of Complete Remission Is Commonly Detected in Acute Myeloid Leukemia (AML) Patients Age ≥60 Years and Significantly Impacts Outcome Based on Post-Remission Treatment Strategies: Prospective Analysis of ECOG-ACRIN (E-A) E2906 Phase III Trial. *Blood*, **2018**, 132, 437-437	2.2	3
217	Prospective, Multi-Center, Phase I Clinical Trial of PLX-R18 Placental Expanded Adherent Stromal Cells in Subjects with Incomplete Hematopoietic Recovery after Hematopoietic Cell Transplantation. *Blood*, **2018**, 132, 3379-3379	2.2	0
216	FLT3-ITD Mutations Are Prevalent and Significantly Impact Outcome after Intensive Therapy in Elderly Adults with Acute Myeloid Leukemia (AML): Analysis of the North American Intergroup E2906 Phase III Trial in Patients Age ≥60 Years. *Blood*, **2018**, 132, 3995-3995	2.2	3
215	Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia. *Blood*, **2018**, 132, 565-565	2.2	1
214	The Predictive Value of Thromboelastogram in the Evaluation of Patients with Suspected Acute Venous Thromboembolism. *Blood*, **2018**, 132, 5052-5052	2.2	
213	Progress and predictions: AML in 2018. *Best Practice and Research in Clinical Haematology*, **2018**, 31, 337-340	4.4	9
212	Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. *Blood Advances*, **2018**, 2, 2922-2936	7.8	17
211	Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 767-775	4.7	27
210	Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. *Blood*, **2017**, 129, 1763-1767	2.2	55
209	Liposomal cytarabine and daunorubicin (CPX-351) for treatment of acute myeloid leukemia. *Expert Opinion on Orphan Drugs*, **2017**, 5, 369-374	1.1	1
208	High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. *Journal of Clinical Oncology*, **2017**, 35, 394-401	2.2	227
207	Treatment of Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia. *Current Treatment Options in Oncology*, **2017**, 18, 20	5.4	5
206	Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials. *Leukemia Research*, **2017**, 59, 55-64	2.7	15
205	Published abstracts at international meetings often over- or underestimate the initial response rate. *Blood*, **2017**, 129, 2326-2328	2.2	6

204	AML in 2017: Advances in clinical practice. *Best Practice and Research in Clinical Haematology*, **2017**, 30, 283-286	4.2	9
203	Which patients should I transplant with acute lymphoblastic leukemia?. *Best Practice and Research in Clinical Haematology*, **2017**, 30, 249-260	4.2	7
202	Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia. *Expert Opinion on Biological Therapy*, **2017**, 17, 1557-1564	5.4	9
201	BST-236. *Journal of Clinical Oncology*, **2017**, 35, e18520-e18520	2.2	
200	Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. *Nature Communications*, **2016**, 7, 13331	17.4	128
199	DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. *Nature Medicine*, **2016**, 22, 1488-1495	50.5	140
198	AML in 2016: Where we are now?. *Best Practice and Research in Clinical Haematology*, **2016**, 29, 315-319	4.2	11
197	Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. *Nature Genetics*, **2016**, 48, 1481-1489	36.3	145
196	Pseudotumor Cerebri in Acute Promyelocytic Leukemia Patients on Intergroup Protocol 0129: Clinical Description and Recommendations for New Diagnostic Criteria. *Clinical Lymphoma, Myeloma and Leukemia*, **2016**, 16, 146-51	2	14
195	Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 1043-1048	4.7	6
194	Adult Nephrotic Syndrome after Hematopoietic Stem Cell Transplantation: Renal Pathology is the Best Predictor of Response to Therapy. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 975-981	4.7	18
193	The Selective Anti Leukemic Effect of BL-8040, a Peptidic CXCR4 Antagonist, Is Mediated By Induction of Leukemic Blast Mobilization, Differentiation and Apoptosis: Results of Correlative Studies from a Ph2a Trial in Acute Myeloid Leukemia. *Blood*, **2016**, 128, 2745-2745	2.2	3
192	Importance of Achieving Complete Remission (CR) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults Age ≥60 Years: Analysis of Risk Factors for Early Mortality and Re-Induction, and Impact of Quality of Response on Overall Survival (OS) in the ECOG-ACRIN E2906 Randomized Trial. *Blood*, **2016**, 128, 339-339	2.2	5
191	Primary Plasma Cell Leukemia Has a Poor Prognosis Even in the Era of Novel Agents - a Multicenter Case Series. *Blood*, **2016**, 128, 5699-5699	2.2	1
190	Astarabine, a Novel Leukemia-Targeted Cytarabine Composition Allows, for the First Time, the Delivery of High Cytarabine Doses for Older or Unfit Patients with Acute Leukemia. Results of an Ongoing Phase I/IIa Study. *Blood*, **2016**, 128, 1650-1650	2.2	
189	A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908). *American Journal of Hematology*, **2016**, 91, 308-12	7.1	9
188	Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. *Cancer*, **2016**, 122, 3005-3014	6.4	32
187	International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. *Haematologica*, **2016**, 101, 1524-1533	6.6	110

186	Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults. *Current Oncology Reports*, **2016**, 18, 39	6.3	27
185	Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. *Blood*, **2016**, 127, 1551-8	2.2	81
184	How I treat acute myeloid leukemia presenting with preexisting comorbidities. *Blood*, **2016**, 128, 488-96	2.2	33
183	Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008. *Journal of Clinical Oncology*, **2016**, 34, 3544-3553	2.2	65
182	Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII. *American Journal of Hematology*, **2016**, 91, 1107-1112	7.1	7
181	Introducing minimal residual disease in acute myeloid leukemia. *Current Opinion in Hematology*, **2015**, 22, 139-45	3.3	8
180	Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia. *Cancer Cell*, **2015**, 28, 343-56	24.3	114
179	Reasons for optimism in the therapy of acute leukemia. *Best Practice and Research in Clinical Haematology*, **2015**, 28, 69-72	4.2	8
178	A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. *Blood*, **2015**, 125, 680-6	2.2	84
177	Severe and persistent heparin-induced thrombocytopenia despite fondaparinux treatment. *American Journal of Hematology*, **2015**, 90, 675-8	7.1	48
176	Secondary acute lymphoblastic leukaemia is constitutional and probably not related to prior therapy. *British Journal of Haematology*, **2015**, 170, 50-5	4.5	19
175	Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the "3 + 7" induction regimen for acute myeloid leukemia. *American Journal of Hematology*, **2015**, 90, 1159-64	7.1	17
174	Impact of Pretransplantation (18)F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 1605-11	4.7	28
173	Tipifarnib As Maintenance Therapy in Acute Myeloid Leukemia (AML) Improves Survival in a Subgroup of Patients with High Risk Disease. Results of the Phase III Intergroup Trial E2902. *Blood*, **2015**, 126, 1308-1308	2.2	5
172	North American Leukemia, Intergroup Phase III Randomized Trial of Single Agent Clofarabine As Induction and Post-Remission Therapy, and Decitabine As Maintenance Therapy in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age ≥60 Years): A Trial of the ECOG-ACRIN Cancer Research Group (E2906). *Blood*, **2015**, 126, 217-217	2.2	24
171	The Peptidic CXCR4 Antagonist, BL-8040, Significantly Reduces Bone Marrow Immature Leukemia Progenitors By Inducing Differentiation, Apoptosis and Mobilization: Results of the Dose Escalation Clinical Trial in Acute Myeloid Leukemia. *Blood*, **2015**, 126, 2546-2546	2.2	12
170	High Frequency and Poor Outcome of Ph-like Acute Lymphoblastic Leukemia in Adults. *Blood*, **2015**, 126, 2618-2618	2.2	4
169	Expression of an Oncogenic ERG isoform Characterizes a Distinct Subtype of B-Progenitor Acute Lymphoblastic Leukemia. *Blood*, **2015**, 126, 693-693	2.2	1

168	Integrated DNA/RNA Profiling for Somatic Alterations in Adult B-Cell ALL. *Blood*, **2015**, 126, 1422-1422	2.2	
167	Very Poor Long-Term Survival, Also in Contemporary Studies, of Patients with AML Who Relapse after Achieving a First Complete Remission: The ECOG-ACRIN Cancer Research Group Experience. *Blood*, **2015**, 126, 1315-1315	2.2	
166	Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. *Nature*, **2014**, 514, 513-7	50.4	271
165	Autologous is superior to allogeneic hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 1021-5	4.7	41
164	Allotransplantation for patients age ≥ 40 years with non-Hodgkin lymphoma: encouraging progression-free survival. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 960-8	4.7	34
163	Younger adults with acute myeloid leukemia in remission for ≥ 3 years have a high likelihood of cure: The ECOG experience in over 1200 patients. *Leukemia Research*, **2014**, 38, 901-6	2.7	10
162	Pathogenesis and prognostication in acute lymphoblastic leukemia. *F1000prime Reports*, **2014**, 6, 59		16
161	UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. *Blood*, **2014**, 123, 843-50	2.2	251
160	Histamine dihydrochloride for maintaining remission in acute myeloid leukemia. *International Journal of Hematologic Oncology*, **2014**, 3, 137-143	1	
159	The increasing genomic complexity of acute myeloid leukemia. *Best Practice and Research in Clinical Haematology*, **2014**, 27, 209-13	4.2	5
158	Transplantation in acute myeloid leukemia. *Hematology/Oncology Clinics of North America*, **2014**, 28, 983-94	3.1	6
157	Single cell analysis exposes intratumor heterogeneity and suggests that FLT3-ITD is a late event in leukemogenesis. *Experimental Hematology*, **2014**, 42, 457-63	3.1	15
156	Minimal Residual Disease Assessment By Flow Cytometry in AML Is an Independant Prognostic Factor Even after Adjusting for Cytogenetic/Molecular Abnormalities. *Blood*, **2014**, 124, 1016-1016	2.2	6
155	Results of the ECOG E1900 Trial in Younger Adults with AML Using an Event Free Survival Endpoint Are Concordant with Results Based on Overall Survival: Potential for a Surrogate Endpoint to Facilitate Rapid Approval of Therapies in AML. *Blood*, **2014**, 124, 2599-2599	2.2	8
154	High Dose Daunorubicin Improves Survival in AML up to Age 60, Across All Cytogenetic Risk Groups Including Patients with Unfavorable Cytogenetic Risk, and FLT3-ITD Mutant AML: Updated Analyses from Eastern Cooperative Oncology Trial E1900. *Blood*, **2014**, 124, 373-373	2.2	5
153	A Randomized Phase II Trial of Three Novel Regimens for Relapsed/ Refractory Acute Myeloid Leukemia (AML) Demonstrates Encouraging Results with a Flavopiridol-Based Regimen: Results of Eastern Cooperative Oncology Group (ECOG) Trial E1906. *Blood*, **2014**, 124, 3742-3742	2.2	5
152	BL-8040, a Peptidic CXCR4 Antagonist, Induces Leukemia Cell Death and Specific Leukemia Cell Mobilization in Relapsed/Refractory Acute Myeloid Leukemia Patients in an Ongoing Phase IIa Clinical Trial. *Blood*, **2014**, 124, 950-950	2.2	11
151	Prevalence and Incidence of Acute Myeloid Leukemia May be Higher Than Currently Accepted Estimates Among the ≥ 65 Year-Old Population in the United States. *Blood*, **2014**, 124, 958-958	2.2	7

150	Telomere Length Recovery Strongly Predicts Overall Survival in Acute Promyelocytic Leukemia. *Blood*, **2014**, 124, 2375-2375	2.2	
149	Early Apoptotic Cells (ApoCell) As Prophylaxis of Graft-Versus-Host Disease in Myeloablative HLA-Matched Allogeneic Bone Marrow Transplantation Is Safe and Effective: 1 Year Follow-up. *Blood*, **2014**, 124, 5866-5866	2.2	
148	A Genome-Wide Association Study of Susceptibility to Acute Lymphoblastic Leukemia in Adolescents and Young Adults. *Blood*, **2014**, 124, 132-132	2.2	0
147	Semaphorin 3A Expression on Donor and Recipient Regulatory Cells: A Novel Pre-Transplant Biomarker Predicting the Development of Acute Graft-Versus-Host Disease. *Blood*, **2014**, 124, 3935-3935	2.2	
146	Delays in Start of Intensification Therapy Are Common for Adults with Acute Lymphoblastic Leukemia, and Are Associated with Decreased Survival in Patients Who Undergo Allogeneic Stem Cell Transplant (SCT). *Blood*, **2014**, 124, 208-208	2.2	
145	Secondary ALL May be Independent of Prior Cytotoxic Therapy. *Blood*, **2014**, 124, 3648-3648	2.2	
144	Determinants of Fatal Bleeding during Induction Therapy for Acute Promyelocytic Leukemia in the ATRA Era. *Blood*, **2014**, 124, 948-948	2.2	1
143	Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. *Cancer Cell*, **2013**, 24, 766-76	24.3	174
142	Important milestones in acute leukemia in 2013. *Best Practice and Research in Clinical Haematology*, **2013**, 26, 241-4	4.2	12
141	High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. *Journal of Clinical Oncology*, **2013**, 31, 676-83	2.2	147
140	Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis. *Leukemia Research*, **2013**, 37, 32-6	2.7	26
139	Genetic profiling in acute myeloid leukaemia--where are we and what is its role in patient management. *British Journal of Haematology*, **2013**, 160, 303-20	4.5	44
138	Is there a role for allogeneic transplantation in chronic myeloid leukemia?. *Expert Review of Hematology*, **2013**, 6, 759-65	2.8	5
137	Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis. *Blood*, **2013**, 121, 339-50	2.2	92
136	The myth of the second remission of acute leukemia in the adult. *Blood*, **2013**, 121, 1077-82	2.2	163
135	Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug. *Blood*, **2013**, 121, 4838-41	2.2	115
134	The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial. *Haematologica*, **2013**, 98, 945-52	6.6	37
133	Updated Efficacy and Safety, and Exploratory Ki-67 Results For The MCL-001 Study Of Lenalidomide In Mantle Cell Lymphoma Patients Who Relapsed Or Were Refractory To Bortezomib. *Blood*, **2013**, 122, 3057-3057	2.2	2

132	Early Bone Marrow Examination, On The Fifth Day Of Induction For AML, Is Highly Predictive Of Response. *Blood*, **2013**, 122, 3893-3893	2.2	1
131	Preemptive Detection Of JC Virus In Peripheral Blood Of Patients Undergoing Allogeneic Stem Cell Transplantation: A Potential Tool To Prevent Progressive Multifocal Leukoencephalopathy In High-Risk Patients?. *Blood*, **2013**, 122, 4537-4537	2.2	1
130	Interpreting outcome data in hematological malignancies: a paradigm for clinical studies. *Rambam Maimonides Medical Journal*, **2013**, 4, e0004	1.8	
129	Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. *British Journal of Haematology*, **2012**, 157, 463-71	4.5	129
128	CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. *Blood*, **2012**, 120, 2297-306	2.2	78
127	How I treat hematologic emergencies in adults with acute leukemia. *Blood*, **2012**, 120, 1993-2002	2.2	48
126	The impact of mutational profiling on AML prognosis. *Best Practice and Research in Clinical Haematology*, **2012**, 25, 403-8	4.2	4
125	Total ambulatory hemato-oncological care: a myth or reality?. *Leukemia and Lymphoma*, **2012**, 53, 2335-6	1.9	6
124	Hyperleukocytosis, leukostasis and leukapheresis: practice management. *Blood Reviews*, **2012**, 26, 117-22	11.1	145
123	Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. *New England Journal of Medicine*, **2012**, 366, 1079-89	59.2	1378
122	Cell lineage analysis of acute leukemia relapse uncovers the role of replication-rate heterogeneity and microsatellite instability. *Blood*, **2012**, 120, 603-12	2.2	59
121	Allogeneic stem cell transplantation for patients with chronic myeloid leukemia: risk stratified approach with a long-term follow-up. *American Journal of Hematology*, **2012**, 87, 875-9	7.1	5
120	Treatment for relapsed acute myeloid leukemia: what is new?. *Current Opinion in Hematology*, **2012**, 19, 89-94	3.3	31
119	IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia. *Journal of Clinical Oncology*, **2012**, 30, 3100-8	2.2	98
118	Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation. *Blood*, **2012**, 120, 578-578	2.2	1
117	R115777(tipifarnib) Improves Early Survival when Used As Maintenance Therapy for Elderly or Relapsed/Refractory Patients with Acute Myelogenous Leukemia in Remission. *Blood*, **2012**, 120, 676-676	2.2	1
116	Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: The MCL-001 (EMERGE) Study. *Blood*, **2012**, 120, 905-905	2.2	5
115	Biology and Outcome of 85 Adults with Acute Lymphoblastic Leukemia (ALL) with t(4;11)/MLL-AF4 Treated in the UKALL XII/ECOG 2993 Study. *Blood*, **2012**, 120, 663-663	2.2	

114	Parallel Transcriptional Analysis of Multiple Stem and Progenitor Populations Identifies Novel Commonly Dysregulated and Functionally Relevant Targets in AML. *Blood*, **2012**, 120, 1875-1875	2.2	
113	Prognostic Relevance of Integrated Genetic Profiling in Adult T-Cell Acute Lymphoblastic Leukemia. *Blood*, **2012**, 120, 294-294	2.2	
112	Practically All Patients with Acute Myeloid Leukemia (AML) in Continuous Complete Remission for 3 Years or More Are Cured of Their Disease: The ECOG Experience. *Blood*, **2012**, 120, 132-132	2.2	
111	Female Donor Allografts Have a Higher CD3 Content Than Male Donor Allografts: Potential Impact On Transplantation Outcomes in Male Recipients. *Blood*, **2012**, 120, 587-587	2.2	
110	Prognostic factors in adult acute leukemia. *Hematology/Oncology Clinics of North America*, **2011**, 25, 1163-87	3.8	8
109	Acute Leukemia **2011**, 235-250		
108	Interpreting data on transplant selection and outcome in adult acute lymphoblastic leukemia (ALL). *Biology of Blood and Marrow Transplantation*, **2011**, 17, S76-83	4.7	8
107	Induction and postremission strategies in acute myeloid leukemia: what is new?. *Current Opinion in Hematology*, **2011**, 18, 83-8	3.3	13
106	Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin. *Blood*, **2011**, 117, 5306-13	2.2	53
105	Assessment of the consistency and robustness of results from a multicenter trial of remission maintenance therapy for acute myeloid leukemia. *Trials*, **2011**, 12, 86	2.8	7
104	Reply to induction therapy and outcome in acute myeloid leukemia. *Cancer*, **2011**, 117, 2237-2237	6.4	1
103	Adding Mercaptopurine and Methotrexate to Alternate Week ATRA Maintenance Therapy Does Not Improve the Outcome for Adults with Acute Promyelocytic Leukemia (APL) in First Remission: Results From North American Leukemia Intergroup Trial C9710. *Blood*, **2011**, 118, 258-258	2.2	5
102	Late Relapses Following All-Trans Retinoic Acid for Acute Promyelocytic Leukemia Are Uncommon, Respond Well to Salvage Therapy and Occur Independently of Prognostic Factors At Diagnosis: Long-Term Follow-up of North American Intergroup Study I0129. *Blood*, **2011**, 118, 83-83	2.2	2
101	Clinical Trial Evaluating DC/AML Fusion Cell Vaccination Alone and in Conjunction with PD-1 Blockade in AML Patients Who Achieve a Chemotherapy-Induced Remission. *Blood*, **2011**, 118, 948-948	2.2	3
100	Six Cycles of BEACOPP Tailored Based on Interim Scintigraphy Provide Favorable Outcome for Patients with Standard and Advanced Risk Hodgkin Lymphoma and Female Fertility Is Preserved: Results of a 10-Year Follow-up. *Blood*, **2011**, 118, 1564-1564	2.2	
99	Administration of All-Trans Retinoic Acid (ATRA) to Newly Diagnosed Patients (pts) with Acute Promyelocytic Leukemia (APL) Is Delayed Even At Experienced Centers and Associated with An Increased Early Death Rate (EDR): A Retrospective Analysis of 205 Pts. *Blood*, **2011**, 118, 942-942	2.2	
98	Young Adults Presenting with Extramedullary Acute Myeloid Leukemia Have A Unique Sensitivity to High Doses of Anthracyclines: Subset Analysis of ECOG 1900,. *Blood*, **2011**, 118, 3619-3619	2.2	
97	Reduced Specificity and Positive Predictive Value of Surveillance FDG-PET/CT for Diffuse Large Cell B Cell Lymphoma in the Rituximab Era. *Blood*, **2011**, 118, 1576-1576	2.2	

96	Post-Engraftment Persistent Leukocytosis May Be An Independent Poor Prognostic Factor in Allogeneic Stem Cell Transplant Patients. *Blood*, **2011**, 118, 4574-4574	2.2	
95	ETV6 Is An Early T-Cell Progenitor (ETP) Specific Tumor Suppressor Gene in Adult T-ALL. *Blood*, **2011**, 118, 406-406	2.2	0
94	Prognostic factors in adult acute lymphoblastic leukaemia. *British Journal of Haematology*, **2010**, 150, 389-405	4.5	95
93	The evolving paradigm of prognostic factors in AML: Introduction to the Acute Leukemia Forum 2010. *Best Practice and Research in Clinical Haematology*, **2010**, 23, 453-6	4.2	1
92	Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. *Blood*, **2010**, 116, 4077-85	2.2	157
91	Induction therapy in acute myeloid leukemia: intensifying and targeting the approach. *Current Opinion in Hematology*, **2010**, 17, 79-84	3.3	7
90	Getting to the root of (it) ALL. *Blood*, **2010**, 115, 3649-50	2.2	2
89	How I treat acute myeloid leukemia. *Blood*, **2010**, 116, 3147-56	2.2	133
88	Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group. *Cancer*, **2010**, 116, 5012-21	6.4	83
87	Imatinib Significantly Enhances Long-Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia; Final Results of the UKALLXII/ECOG2993 Trial. *Blood*, **2010**, 116, 169-169	2.2	9
86	BKT140 Is a Novel CXCR4 Antagonist with Stem Cell Mobilization and Antimyeloma Effects: An Open-Label First Human Trial In Patients with Multiple Myeloma Undergoing Stem Cell Mobilization for Autologous Transplantation. *Blood*, **2010**, 116, 2260-2260	2.2	9
85	Maintenance Rituximab Every 2 Months for 2 Years Is Effective and Well Tolerated In Patients with Follicular Lymphoma with Both Standard or Rapid Infusion: Updated Results From the Phase IIIb MAXIMA Study. *Blood*, **2010**, 116, 3945-3945	2.2	2
84	Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL): Results From the International MRC/ECOG Trial. *Blood*, **2010**, 116, 493-493	2.2	2
83	Outcome of 1,229 Adult Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia (B-ALL) Patients (pts) From the International UKALLXII/E2993 Trial: No Difference In Results Between B Cell Immunophenotypic Subgroups. *Blood*, **2010**, 116, 524-524	2.2	5
82	High-Throughput Mutational Profiling In AML: Mutational Analysis of the ECOG E1900 Trial. *Blood*, **2010**, 116, 851-851	2.2	1
81	A Population-Based Study In Acute Promyelocytic Leukemia (APL) Suggests a Higher Early Death Rate and Lower Overall Survival Than Commonly Reported In Clinical Trials: Data From the Surveillance, Epidemiology, and End Results (SEER) Program and the New York State Cancer	2.2	2
80	A Multi-Center Prospective Randomized Study Comparing Ibritumomab Tiuxetan (Zevalin) and High-Dose BEAM Chemotherapy (Z-BEAM) Vs. BEAM Alone as the Conditioning Regimen Prior to Autologous Stem-Cell Transplantation In Patients with Aggressive Lymphoma; Possible Advantage for Z-BEAM In Low-Risk Patients. *Blood*, **2010**, 116, 686-686	2.2	1
79	BCL11B Mutations In T-Cell Acute Lymphoblastic Leukemia. *Blood*, **2010**, 116, 471-471	2.2	

78	Increased Incidence of Therapy Related Myeloid Neoplasia (t-MN) After Initial Therapy for CLL with Fludarabine-Cyclophosphamide (FC) Vs Fludarabine (F): Long-Term Follow-up of US Intergroup Study E2997. *Blood*, **2010**, 116, 924-924	2.2	
77	Single-Cell Phylogenetic analysis provides Novel Insight Into Resistance Mechanisms In AML. *Blood*, **2010**, 116, 178-178	2.2	
76	Tipifarnib Is Well Tolerated as Maintenance Therapy In Acute Myeloid Leukemia (AML). Significant, but Non-Fatal, Hematologic Toxicity Not Ameliorated by Dose Reduction. Preliminary Results of the Phase III Intergroup Trial E2902. *Blood*, **2010**, 116, 3315-3315	2.2	1
75	Integrative Genome-Wide DNA Methylation and Gene Expression Analysis Reveals Biological and Clinical Insights In Adult Acute Lymphoblastic Leukemia. *Blood*, **2010**, 116, 852-852	2.2	0
74	Cytogenetics Abnormalities Predict the Outcome of Allogeneic Transplantation In AML: A CIBMTR Study. *Blood*, **2010**, 116, 680-680	2.2	
73	Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol. *Journal of Clinical Oncology*, **2009**, 27, 4352-6	2.2	84
72	Optimal induction and post-remission therapy for AML in first remission. *Hematology American Society of Hematology Education Program*, **2009**, 396-405	3.1	67
71	Transplantation in adult ALL. *Hematology American Society of Hematology Education Program*, **2009**, 593-601	3.1	16
70	Anthracycline dose intensification in acute myeloid leukemia. *New England Journal of Medicine*, **2009**, 361, 1249-59	59.2	658
69	Optimal management of adults with ALL. *British Journal of Haematology*, **2009**, 144, 468-83	4.5	40
68	Is there a role for intensifying induction therapy in acute myeloid leukaemia (AML)?. *Best Practice and Research in Clinical Haematology*, **2009**, 22, 509-15	4.2	3
67	T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). *Blood*, **2009**, 114, 5136-45	2.2	277
66	Closer to the truth in AML. *Blood*, **2009**, 113, 4129-30	2.2	8
65	Hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia. *Current Opinion in Hematology*, **2009**, 16, 453-9	3.3	6
64	Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. *Blood*, **2009**, 113, 4489-96	2.2	214
63	Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies – A Curative Approach When Performed as a Primary Therapeutic Modality: A Single Center Experience.. *Blood*, **2009**, 114, 1144-1144	2.2	
62	Dendritic Cell Tumor Fusion Vaccination in Conjunction with Autologous Transplantation for Multiple Myeloma.. *Blood*, **2009**, 114, 783-783	2.2	
61	Prior Response to Imatinib Predicts Response to Second Line Treatment with Nilotinib in CML Patients Resistant or Intolerant to Imatinib.. *Blood*, **2009**, 114, 3297-3297	2.2	

60	Why is clinical progress in acute myelogenous leukemia so slow?. *Best Practice and Research in Clinical Haematology*, **2008**, 21, 1-3	4.2	8
59	Consolidation therapy: what should be the standard of care?. *Best Practice and Research in Clinical Haematology*, **2008**, 21, 53-60	4.2	11
58	Graft-versus-disease effect following allogeneic transplantation for acute leukaemia. *Best Practice and Research in Clinical Haematology*, **2008**, 21, 485-502	4.2	13
57	Clinical progress in acute myeloid leukemia. Preface. *Best Practice and Research in Clinical Haematology*, **2008**, 21, 597-9	4.2	1
56	Indications for hematopoietic cell transplantation in acute leukemia. *Biology of Blood and Marrow Transplantation*, **2008**, 14, 154-64	4.7	7
55	In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). *Blood*, **2008**, 111, 1827-33	2.2	590
54	Response: Chemotherapy or allografting for young adults with high-risk ALL?. *Blood*, **2008**, 111, 5755	2.2	7
53	Treatment-Related Mortality and Relapse Rate from Time of Initiation of Post-Remission Therapy for Patients Receiving Allogeneic Transplantation, Autologous Transplantation or Intensive Chemotherapy: A Report from the Eastern Cooperative Oncology Group (ECOG). *Blood*, **2008**, 112, 49-49	2.2	3
52	Fusion Cell Vaccination in Conjunction with Stem Cell Transplantation Is Well Tolerated, Induces Anti-Tumor Immunity and Is Associated with Responses in Patients with Multiple Myeloma. *Blood*, **2008**, 112, 826-826	2.2	1
51	Induced CD4+CD25+ FOXP-3+ and CD8+CD25+ FOXP-3+t Cells Exhibit a Concurrent Expression of Effector and Selective Suppressive Capacities. *Blood*, **2008**, 112, 3501-3501	2.2	
50	Innovative approaches in the treatment and support of patients with acute myelogenous leukemia. *Oncologist*, **2007**, 12 Suppl 2, 1	5.7	74
49	Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. *Blood*, **2007**, 109, 3189-97	2.2	564
48	Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias. *Journal of Clinical Oncology*, **2007**, 25, 1341-9	2.2	88
47	Recent developments in acute myelogenous leukemia therapy. *Oncologist*, **2007**, 12 Suppl 2, 14-21	5.7	17
46	Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. *Blood*, **2007**, 109, 944-50	2.2	594
45	Closing the gap in CML. *Blood*, **2007**, 109, 2271-2271	2.2	1
44	How I treat acute lymphocytic leukemia in adults. *Blood*, **2007**, 110, 2268-75	2.2	30
43	Alternative donor transplantation in acute myeloid leukemia: which source and when?. *Current Opinion in Hematology*, **2007**, 14, 152-61	3.3	18

42	Post-Consolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in AML: Long Term Follow-Up of Leukemia-Free Survival and Overall Survival.. *Blood*, **2007**, 110, 1846-1846	2.2	1
41	Impact on Quality of Life of Postconsolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in Acute Myelogenous Leukemia.. *Blood*, **2007**, 110, 4381-4381	2.2	1
40	Does Imatinib Change the Outcome in Philapdelphia Chromosome Positive Acute Lymphoblastic Leukaemia in Adults? Data from the UKALLXII/ECOG2993 Study.. *Blood*, **2007**, 110, 8-8	2.2	18
39	Preface: significant advances in the biology and therapy of AML over the past four decades. *Best Practice and Research in Clinical Haematology*, **2006**, 19, 259-62	4.2	2
38	Is there a role for consolidation therapy pre-transplantation?. *Best Practice and Research in Clinical Haematology*, **2006**, 19, 301-10	4.2	3
37	Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. *Blood*, **2006**, 108, 88-96	2.2	183
36	Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. *Blood*, **2006**, 108, 465-72	2.2	163
35	In Adults with Standard-Risk Acute Lymphoblastic Leukemia (ALL) the Greatest Benefit Is Achieved from an Allogeneic Transplant in First Complete Remission (CR) and an Autologous Transplant Is Less Effective Than Conventional Consolidation/Maintenance Chemotherapy: Final Results of the	2.2	6
34	Allogeneic Stem Cell Transplantation (ASCT) in CML with Partial T-Cell Depletion, No Prophylaxis for Graft-Versus-Host Disease (GvHD) and Preemptive DLI for Patients with Post-Transplant Minimal Residual Disease (MRD): An Alternative Approach in CML Transplantation with Low Morbidity and Long Term Disease Free Survival.. *Blood*, **2006**, 108, 318-318	2.2	1
33	Expansion of Hematopoietic Stem Cells (HSC) from Cord-Blood (CB) Derived Mononuclear Cells (MNC) in Cytokine-Free Environment Using Mesenchymal Cells Spatial Co-Culture System.. *Blood*, **2006**, 108, 2565-2565	2.2	
32	Differential Gene Expression Patterns and Interaction Networks in BCR/ABL Positive and Negative Adult Acute Lymphoblastic Leukemias.. *Blood*, **2006**, 108, 1836-1836	2.2	
31	Early Interim Negative FDG-PET/CT Is a High Predictive Factor for Progression-Free Survival in Hodgkin Lymphoma.. *Blood*, **2006**, 108, 4589-4589	2.2	
30	Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: an Eastern Cooperative Oncology Group trial (E4995). *Leukemia and Lymphoma*, **2005**, 46, 55-61	1.9	20
29	Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. *Blood*, **2005**, 106, 3760-7	2.2	494
28	Prognostic factors in acute myeloid leukemia. *Current Opinion in Hematology*, **2005**, 12, 62-7	3.3	30
27	Drug therapy for acute myeloid leukemia. *Blood*, **2005**, 106, 1154-63	2.2	521
26	Very Poor Survival of Patients with AML Who Relapse after Achieving a First Complete Remission: The Eastern Cooperative Oncology Group Experience.. *Blood*, **2005**, 106, 546-546	2.2	18
25	Outcomes of Unrelated Cord Blood and Haploidentical Stem Cell Transplantation in Adults with Acute Leukaemia.. *Blood*, **2005**, 106, 301-301	2.2	3

24	Use of Dendritic Cells Versus Peripheral Blood Lymphocytes To Segregate Alloreactive and Regulatory T Cells during Allogeneic Transplantation.. *Blood*, **2005**, 106, 5244-5244	2.2	
23	Karyotype Is an Independent Prognostic Factor in Adult Acute Lymphoblastic Leukaemia (ALL): Analysis of Cytogenetic Data from 1,235 Patients on the Medical Research Council (MRC) UKALLXII /Eastern Cooperative Oncology Group (ECOG) 2993 Trial.. *Blood*, **2005**, 106, 331-331	2.2	1
22	Risk Adapted BEACOPP Regimen Based on Early Scintigraphy Can Reduce the Cumulative Dose of Chemotherapy for Standard and High Risk Hodgkin Lymphoma (HD) with No Impairment of Outcome.. *Blood*, **2005**, 106, 815-815	2.2	
21	Phase III Trial of All-Trans Retinoic Acid (ATRA) vs Daunorubicin (D) and Cytosine Arabinoside (A) as Induction Therapy and ATRA vs Observation as Maintenance Therapy for Children with Newly Diagnosed Acute Promyelocytic Leukemia (APL).. *Blood*, **2005**, 106, 894-894	2.2	
20	Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). *Journal of Clinical Oncology*, **2004**, 22, 1078-86	2.2	198
19	Acute monocytic leukemia (French-American-British classification M5) does not have a worse prognosis than other subtypes of acute myeloid leukemia: a report from the Eastern Cooperative Oncology Group. *Journal of Clinical Oncology*, **2004**, 22, 1276-86	2.2	57
18	State of the science for myelodysplastic syndrome: prognosis and promise of new therapies. *Best Practice and Research in Clinical Haematology*, **2004**, 17, 535-541	4.2	2
17	A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. *Blood*, **2004**, 103, 479-85	2.2	238
16	Improved Leukemia-Free Survival after Post-Consolidation Treatment with Histamine Dihydrochloride and Interleukin-2 in AML: A Randomized Phase III Trial.. *Blood*, **2004**, 104, 261-261	2.2	5
15	CA-125 as a Marker for the Early Diagnosis of Hepatic Veno-Occlusive Disease Following Hematopoietic Stem Cell Transplantation.. *Blood*, **2004**, 104, 1138-1138	2.2	
14	Risk Factors for Outcomes of Family Haploidentical Allogeneic Stem Cell Transplantation for Adults with Acute Leukemias: A Survey on Behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).. *Blood*, **2004**, 104, 2146-2146	2.2	
13	State of the science for myelodysplastic syndrome: prognosis and promise of new therapies. *Best Practice and Research in Clinical Haematology*, **2004**, 17, 535-41	4.2	0
12	Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): an Eastern Cooperative Oncology Group Study. *American Journal of Hematology*, **2001**, 66, 23-7	7.1	8
11	Rare adult acute lymphocytic leukemia with CD56 expression in the ECOG experience shows unexpected phenotypic and genotypic heterogeneity. *American Journal of Hematology*, **2001**, 66, 189-96	7.1	32
10	Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: before and after chemoprophylaxis and institution of HEPA filters. *American Journal of Hematology*, **2001**, 66, 257-62	7.1	177
9	Acute myeloid leukemia. *Hematology American Society of Hematology Education Program*, **2001**, 2001, 62-86	3.1	90
8	Concurrent use of growth factors and chemotherapy in acute leukemia. *Current Opinion in Hematology*, **2000**, 7, 197-202	3.3	6
7	Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. *Blood*, **2000**, 96, 4075-4083	2.2	1304

6	Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. *New England Journal of Medicine*, **1998**, 339, 1649-56	59.2	506
5	All-trans-retinoic acid in acute promyelocytic leukemia. *New England Journal of Medicine*, **1997**, 337, 1021-8	59.2	895
4	Intensifying Induction Therapy in Acute Myeloid Leukemia: Has a New Standard of Care Emerged?. *Blood*, **1997**, 90, 2121-2126	2.2	44
3	Effects of GM-CSF on Ki67 expression and cell cycle traverse in acute myelogenous leukemia specimens and cell lines. *Leukemia Research*, **1994**, 18, 609-16	2.7	7
2	Leukaemia427-448		
1	Leukaemia427-448		